<DOC>
	<DOCNO>NCT01632579</DOCNO>
	<brief_summary>This phase I study LY3023703 healthy participant . The purpose study look safety , well study drug tolerate , much study drug get blood stream , long take body get rid give human . Information side effect may occur also collect . Participants remain study approximately 3 month . This study research purpose intend treat medical condition .</brief_summary>
	<brief_title>A Single Dose Study LY3023703 Healthy Participants</brief_title>
	<detailed_description />
	<mesh_term>Celecoxib</mesh_term>
	<criteria>Overtly healthy individual base history physical examination determine investigator Body mass index 18.5 32.0 kilogram per square meter ( kg/m^2 ) , inclusive Have know allergy LY3023703 component formulation , celecoxib , sulfonamide . Participants know aspirin allergy , allergic reaction nonsteroidal antiinflammatory drug ( NSAIDs ) , allergies intolerance selective microsomal prostaglandin E synthase ( mPGES1 ) inhibitor also exclude Have presence active peptic ulcer disease , gastrointestinal ( GI ) bleeding , chronic gastritis , inflammatory bowel disease , chronic diarrhea , positive Helicobacter pylorus serology Use NSAIDs , celecoxib , aspirin , acetaminophen ( dose great 1 gram per day ) within 14 day screen</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>September 2012</verification_date>
</DOC>